NEW YORK, December 29, 2025, 23:17 ET — Market closed
- Medtronic shares closed down 0.4% at $96.15 in the final full week of 2025 trading.
- Wall Street dipped from record levels in light volume, keeping the focus on rates and the Fed’s next move.
- Investors are watching Tuesday’s Fed minutes and Medtronic’s next earnings date on Feb. 17.
Medtronic plc shares edged lower on Monday, closing down about 0.4% at $96.15, in a quiet start to the market’s final three sessions of the year.
The move mattered less for the size of the drop than for what it signaled: investors are de-risking into year-end while waiting for fresh clues on interest rates, a key input for valuing big, cash-generating healthcare names.
“Volume is low, so any activity could push the index one way or the other,” said Sam Stovall, chief investment strategist at CFRA Research, adding that some investors may be doing “tax loss harvesting” — selling losers to offset taxable gains. Kitco
U.S. stocks broadly slipped, with the S&P 500 down 0.35% and the Nasdaq off 0.50%, while Treasury yields eased as markets priced in further Federal Reserve rate cuts next year.
Medtronic’s decline came without a fresh corporate announcement on the company’s press-release page, leaving traders to point to macro positioning rather than a single stock-specific headline.
The medical-device maker has, however, been in the market’s frame after saying earlier this month that its diabetes business — which will operate under the name MiniMed — filed a registration statement on Form S-1, the SEC document companies use to go public.
A MiniMed listing would sharpen the spotlight on a business that competes in and around continuous glucose monitors (CGMs), which track glucose levels through a wearable sensor, and insulin-delivery devices — a crowded field that includes Abbott and Dexcom among the larger names.
For Medtronic investors, the year-end drift also reflects a broader question: how much of 2026’s rate outlook is already in the stock, after the market’s rally left many large-cap defensives trading closer to the top of their annual ranges.
Before the next session, the main market catalyst is the release of minutes from the Fed’s Dec. 9–10 meeting at 2:00 p.m. ET on Tuesday — a detailed account that traders use to gauge how policymakers are leaning on future rate cuts.
Investors will also parse Tuesday’s U.S. data slate, including the S&P Case-Shiller home price index and the Chicago PMI survey, which can move yields and risk appetite in thin holiday liquidity.
The next scheduled Medtronic company milestone is earnings. Medtronic said it plans to report fiscal 2026 third-quarter results on Tuesday, Feb. 17, with fourth-quarter results slated for May 20.
Technically, the stock is trading in the middle of its 52-week range of roughly $79.29 to $106.33, leaving investors watching whether it can reclaim the $100 level into early 2026 as rate expectations and updates on the MiniMed separation come into clearer view.
